688192 迪哲医药-U
已收盘 11-05 15:00:00
资讯
新帖
简况
毛利率“变脸王”频出，谁在真赚钱？拆解2026年三季报中“真拐点与假繁荣”
东方财富网 · 17:33
毛利率“变脸王”频出，谁在真赚钱？拆解2026年三季报中“真拐点与假繁荣”
迪哲医药(688192.SH)：血液瘤产品多项研究成果入选第68届美国血液学会(ASH)年会
智通财经 · 16:17
迪哲医药(688192.SH)：血液瘤产品多项研究成果入选第68届美国血液学会(ASH)年会
迪哲医药（688192）11月4日主力资金净卖出403.78万元
证券之星 · 08:32
迪哲医药（688192）11月4日主力资金净卖出403.78万元
迪哲医药（688192）11月2日主力资金净买入3646.14万元
证券之星 · 11-03 08:16
迪哲医药（688192）11月2日主力资金净买入3646.14万元
迪哲医药（688192）披露2026年第三季度报告，10月30日股价上涨0.7%
证券之星 · 10-30
迪哲医药（688192）披露2026年第三季度报告，10月30日股价上涨0.7%
迪哲医药(688192)9月30日股东户数1.34万户，较上期增加3.96%
证券之星 · 10-30
迪哲医药(688192)9月30日股东户数1.34万户，较上期增加3.96%
迪哲医药(688192.SH)发布前三季度业绩，归母净利润36.39亿元
智通财经 · 10-30
迪哲医药(688192.SH)发布前三季度业绩，归母净利润36.39亿元
迪哲医药（688192）10月27日主力资金净卖出2748.95万元
证券之星 · 10-28
迪哲医药（688192）10月27日主力资金净卖出2748.95万元
迪哲医药（688192）10月23日主力资金净卖出1111.93万元
证券之星 · 10-24
迪哲医药（688192）10月23日主力资金净卖出1111.93万元
迪哲医药（688192）10月20日主力资金净卖出1441.66万元
证券之星 · 10-21
迪哲医药（688192）10月20日主力资金净卖出1441.66万元
迪哲医药（688192）10月13日主力资金净买入348.45万元
证券之星 · 10-14
迪哲医药（688192）10月13日主力资金净买入348.45万元
迪哲医药（688192）9月24日主力资金净卖出1437.14万元
证券之星 · 09-25
迪哲医药（688192）9月24日主力资金净卖出1437.14万元
每周股票复盘：迪哲医药（688192）比瑞替尼治疗DLBCL客观缓解率达47.6%
证券之星 · 09-13
每周股票复盘：迪哲医药（688192）比瑞替尼治疗DLBCL客观缓解率达47.6%
迪哲医药（688192）披露比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表，9月10日股价下跌0.95%
证券之星 · 09-10
迪哲医药（688192）披露比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表，9月10日股价下跌0.95%
迪哲医药(688192.SH)：比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表
智通财经 · 09-09
迪哲医药(688192.SH)：比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表
每周股票复盘：迪哲医药（688192）舒沃哲一线治疗肺癌适应症获FDA受理
证券之星 · 09-06
每周股票复盘：迪哲医药（688192）舒沃哲一线治疗肺癌适应症获FDA受理
迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效
智通财经 · 09-01
迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效
迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%
证券之星 · 08-31
迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%
迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资
智通财经 · 08-28
迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资
每周股票复盘：迪哲医药（688192）股东户数增18.73%
证券之星 · 08-23
每周股票复盘：迪哲医药（688192）股东户数增18.73%
暂无数据
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药-U","latestPrice":67.56,"timestamp":1793862000000,"preClose":64.1,"halted":0,"volume":10405188,"delay":0,"changeRate":0.054,"floatShares":461000000,"shares":465000000,"eps":7.4268,"marketStatus":"已收盘","change":3.46,"latestTime":"11-05 15:00:00","open":63.62,"high":67.58,"low":63.5,"amount":692000000,"amplitude":0.0637,"askPrice":67.57,"askSize":412,"bidPrice":67.56,"bidSize":2,"shortable":0,"etf":0,"ttmEps":7.4268,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793928600000},"marketStatusCode":5,"adr":0,"adjPreClose":64.1,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793842200000,1793849400000],[1793854800000,1793862000000]],"highLimit":70.51,"lowLimit":57.69,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":465165842,"isCdr":false,"pbRate":6.31,"roa":"--","peRate":9.096785,"roe":"115.44%","epsLYR":-1.71,"committee":-0.125541,"marketValue":31427000000,"turnoverRate":0.0226,"status":0,"afterMarket":{"amount":108096,"volume":1600,"close":67.56,"buyVolume":823,"sellVolume":0,"time":1793864037746,"indexStatus":"已收盘 11-05 15:30:00","preClose":64.1},"floatMarketCap":31160000000},"requestUrl":"/m/hq/s/688192/tweets","defaultTab":"tweets","newsList":[{"id":"2681406780","title":"毛利率“变脸王”频出，谁在真赚钱？拆解2026年三季报中“真拐点与假繁荣”","url":"https://stock-news.laohu8.com/highlight/detail?id=2681406780","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681406780?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:33","pubTimestamp":1793871197,"startTime":"0","endTime":"0","summary":"一边是毛利率高达99%的“躺赚”神话，一边却是-512%的“做一单亏一单”深渊。2026年三季报即将落下帷幕，财报数据呈现出了极致的“冰火两重天”。在这个财报季，到底该如何撕开数据表象，发现哪些公司的改善是“真拐点”，哪些只是“账面修复”，又有哪些是数字“幻觉”？答案，藏在两组关键数据的交叉验证之中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202611053923597196.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202611053923597196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["BK0224","BK0188","BK0075","688303","BK0178","BK0241","TNmain","ZFmain","002059","600674","BK0146","UBmain","BK0114","688192","BK0183","ZNmain","688382","BK0251","002343","BK0261","300357","688197","BK0077","BK0087","BK0276","BK0102","BK0218","BK0012","BK0059","600996","688302","BK0201","600783","BK0101","BK0267","ZBmain","BK0094","688765","688670","BK0239","BK0109","BK0196","002432","300093","BK0271","BK0028","BK0235","300197","ZTmain","BK0145"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681049058","title":"迪哲医药(688192.SH)：血液瘤产品多项研究成果入选第68届美国血液学会(ASH)年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2681049058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681049058?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:17","pubTimestamp":1793866675,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药 发布公告，公司将于12月12日至15日在美国新奥尔良举办的第68届美国血液学会年会上，公布血液肿瘤管线的8项最新临床研究成果，包含3项口头报告和5项壁报展示，涉及公司血液瘤领域的三大核心产品——高选择性JAK1抑制剂高瑞哲、LYN/BTK双靶点抑制剂比瑞替尼以及新一代EZH1/2双靶点小分子抑制剂GW5282。此次大会上高瑞哲共有5项最新临床研究进展入选。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4109","BK1574","ASH","BK0239","159938","BK1161","BK1515","LU2463526074.USD","688192","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681097518","title":"迪哲医药（688192）11月4日主力资金净卖出403.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681097518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681097518?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:32","pubTimestamp":1793838728,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月4日收盘，迪哲医药报收于64.1元，上涨8.35%，换手率2.0%，成交量9.24万手，成交额5.7亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入6455.94万元，融资偿还3643.29万元，融资净买入2812.65万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500009906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","09939","BK1161","688192","BK0239","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680794044","title":"迪哲医药（688192）11月2日主力资金净买入3646.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680794044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680794044?lang=zh_cn&edition=full","pubTime":"2026-11-03 08:16","pubTimestamp":1793664979,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月2日收盘，迪哲医药报收于61.07元，上涨9.5%，换手率2.74%，成交量12.62万手，成交额7.38亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入5713.2万元，融资偿还5812.21万元，融资净偿还99.01万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300010244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688192","09939","BK1574","BK1515","BK0239","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679572243","title":"迪哲医药（688192）披露2026年第三季度报告，10月30日股价上涨0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679572243","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679572243?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:58","pubTimestamp":1793372324,"startTime":"0","endTime":"0","summary":"截至2026年10月30日收盘，迪哲医药报收于55.77元，较前一交易日上涨0.7%，最新总市值为259.42亿元。该股当日开盘55.4元，最高57.5元，最低53.82元，成交额达2.78亿元，换手率为1.08%。近日，迪哲医药发布2026年第三季度报告。报告显示，本报告期营业收入为4,246,871,524.03元，较上年同期增长1,736.09%；归属于上市公司股东的净利润为3,849,148,688.39元。年初至报告期末，营业收入为4,769,564,247.74元，同比增长713.50%；归属于上市公司股东的净利润为3,638,775,318.30元。研发投入合计593,244,735.77元，占营业收入比例为12.44%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000057984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","688192","159938","BK0239","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679218064","title":"迪哲医药(688192)9月30日股东户数1.34万户，较上期增加3.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679218064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679218064?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:11","pubTimestamp":1793358684,"startTime":"0","endTime":"0","summary":"证券之星消息，近日迪哲医药披露，截至2026年9月30日公司股东户数为1.34万户，较6月30日增加512.0户，增幅为3.96%。在化学制药行业个股中，迪哲医药股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.98万户。从股价来看，2026年6月30日至2026年9月30日，迪哲医药区间涨幅为45.28%，在此期间股东户数增加512.0户，增幅为3.96%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000046516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1515","09939","BK1161","688192","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679267373","title":"迪哲医药(688192.SH)发布前三季度业绩，归母净利润36.39亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679267373","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679267373?lang=zh_cn&edition=full","pubTime":"2026-10-30 15:46","pubTimestamp":1793346391,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布2026年三季度报告，前三季度，公司实现营业收入47.7亿元，同比增长713.50%。归属于上市公司股东的净利润36.39亿元，归属于上市公司股东的扣除非经常性损益的净利润36.12亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678748046","title":"迪哲医药（688192）10月27日主力资金净卖出2748.95万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678748046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678748046?lang=zh_cn&edition=full","pubTime":"2026-10-28 08:46","pubTimestamp":1793148390,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月27日收盘，迪哲医药报收于57.4元，下跌5.98%，换手率1.25%，成交量5.76万手，成交额3.38亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2389.21万元，融资偿还2487.05万元，融资净偿还97.84万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800014250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239","BK1161","BK1515","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677036959","title":"迪哲医药（688192）10月23日主力资金净卖出1111.93万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677036959","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677036959?lang=zh_cn&edition=full","pubTime":"2026-10-24 08:16","pubTimestamp":1792800988,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月23日收盘，迪哲医药报收于63.34元，上涨6.01%，换手率1.55%，成交量7.15万手，成交额4.4亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2991.09万元，融资偿还2789.15万元，融资净买入201.94万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400006822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","09939","159938","BK1161","BK1515","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677107266","title":"迪哲医药（688192）10月20日主力资金净卖出1441.66万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677107266","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677107266?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:28","pubTimestamp":1792542534,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月20日收盘，迪哲医药报收于61.4元，下跌2.85%，换手率1.23%，成交量5.66万手，成交额3.47亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2784.47万元，融资偿还1852.98万元，融资净买入931.49万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100007175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1574","BK1161","09939","688192","BK0239","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675951673","title":"迪哲医药（688192）10月13日主力资金净买入348.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675951673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675951673?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:14","pubTimestamp":1791936846,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，迪哲医药报收于61.9元，上涨7.76%，换手率2.03%，成交量9.37万手，成交额5.64亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2281.94万元，融资偿还3997.64万元，融资净偿还1715.7万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400006914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","09939","688192","BK1161","159938","BK0239","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670419940","title":"迪哲医药（688192）9月24日主力资金净卖出1437.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670419940","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670419940?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:23","pubTimestamp":1790295809,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，迪哲医药报收于56.45元，下跌6.31%，换手率1.41%，成交量6.52万手，成交额3.74亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2711.56万元，融资偿还3926.96万元，融资净偿还1215.39万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1515","09939","BK1161","688192","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507699","title":"每周股票复盘：迪哲医药（688192）比瑞替尼治疗DLBCL客观缓解率达47.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507699","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507699?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:02","pubTimestamp":1789236137,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，迪哲医药报收于53.07元，较上周的57.07元下跌7.01%。本周，迪哲医药9月7日盘中最高价报57.85元。本周关注点公司公告汇总：比瑞替尼治疗r/r DLBCL的II期临床研究结果显示整体客观缓解率达47.6%。公司公告汇总迪哲医药自愿披露，其自主研发的全球首创LYN/BTK双靶点抑制剂比瑞替尼单药治疗复发/难治弥漫性大B细胞淋巴瘤的II期临床研究结果已在《血液肿瘤期刊》发表。安全性方面可控，未报告药物相关的大出血或房颤事件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","09939","BK0239","BK1161","688192","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666561405","title":"迪哲医药（688192）披露比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表，9月10日股价下跌0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666561405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666561405?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:32","pubTimestamp":1789032727,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，迪哲医药报收于54.38元，较前一交易日下跌0.95%，最新总市值为252.96亿元。该股当日开盘54.92元，最高55.45元，最低53.71元，成交额达1.79亿元，换手率为0.71%。迪哲（江苏）医药股份有限公司于近日披露公告，其自主研发的全球首创LYN/BTK双靶点抑制剂比瑞替尼单药治疗复发/难治弥漫性大B细胞淋巴瘤的II期临床研究结果已在国际权威期刊《血液肿瘤期刊》发表。安全性可控，未报告药物相关的大出血或房颤事件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000031585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","09939","BK0239","BK1574","BK1515","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666583145","title":"迪哲医药(688192.SH)：比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2666583145","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666583145?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:56","pubTimestamp":1788940569,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药 发布公告，公司自主研发的全球首创、可完全穿透血脑屏障的非共价LYN/BTK双靶点抑制剂比瑞替尼单药治疗复发/难治弥漫性大B细胞淋巴瘤II期临床研究结果正式发表于国际权威血液学期刊《血液肿瘤期刊》。TAI-SHAN9研究入组患者既往接受过1至5线系统性治疗。研究结果显示，在50mg和75mg剂量下，比瑞替尼单药治疗在不同分子亚型中均展现出广谱的抗肿瘤活性，并呈现出可管理的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","159938","BK0239","09939","688192","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665567365","title":"每周股票复盘：迪哲医药（688192）舒沃哲一线治疗肺癌适应症获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2665567365","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665567365?lang=zh_cn&edition=full","pubTime":"2026-09-06 01:30","pubTimestamp":1788629429,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，迪哲医药报收于57.07元，较上周的58.67元下跌2.73%。本周，迪哲医药9月3日盘中最高价报60.69元。本周关注点来自公司公告汇总：舒沃哲新增适应症上市申请获美国FDA受理，拟用于一线治疗EGFR exon20ins非小细胞肺癌。此前，舒沃哲已获中美两国突破性疗法认定，并已在中美获批用于二线及后线治疗。迪哲医药与阿斯利康签署的《许可协议》已于2026年8月31日正式生效，授权阿斯利康在全球范围内独家开发和商业化舒沃哲。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0239","09939","688192","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881161","title":"迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881161","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664881161?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:44","pubTimestamp":1788223497,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2026年7月14日与AstraZeneca UK Limited(以下简称“阿斯利康”)签署《许可协议》，授予阿斯利康在全球范围内独家开发、商业化舒沃哲®的权利。协议约定的协议生效条件已全部满足，协议于2026年8月31日正式生效。阿斯利康将于今年第四季度在美国实现舒沃哲®商业化。公司将获得阿斯利康支付的一次性、不可返还的首付款6亿美元，最高达4 亿美元的临床开发里程碑款项以及最高达5亿美元的销售里程碑款项，此外公司将获得按舒沃哲®全球销售额最高到低双位数的阶梯式比例的特许权使用费。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1515","159938","BK1574","688192","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071350","title":"迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071350","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663071350?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:44","pubTimestamp":1788169497,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，迪哲医药报收于58.28元，较前一交易日下跌0.66%，最新总市值为271.1亿元。该股当日开盘57.87元，最高59.58元，最低57.5元，成交额达3.55亿元，换手率为1.32%。迪哲医药近日披露公告，公司自主研发的舒沃哲新增适应症上市申请已获美国FDA受理，拟用于一线治疗EGFR exon20ins的局部晚期或转移性非小细胞肺癌成人患者。该适应症在中国也已获NMPA受理并纳入优先审评，此前已获中美突破性疗法认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100024818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1574","159938","688192","BK1515","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662034757","title":"迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资","url":"https://stock-news.laohu8.com/highlight/detail?id=2662034757","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662034757?lang=zh_cn&edition=full","pubTime":"2026-08-28 08:25","pubTimestamp":1787876738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2026年8月27日重新向香港联合交易所有限公司(以下简称“香港联交所”)递交了发行H股股票并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请材料。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","688192","BK0239","BK1161","BK1515","09939","IPOS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661110862","title":"每周股票复盘：迪哲医药（688192）股东户数增18.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661110862","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661110862?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:53","pubTimestamp":1787424789,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，迪哲医药报收于59.0元，较上周的60.91元下跌3.14%。本周，迪哲医药8月18日盘中最高价报62.65元。公司公告汇总：公司与阿斯利康签署许可协议，授予舒沃哲全球独家开发和商业化权利，获得6亿美元首付款。股本股东变化截至2026年6月30日，公司股东户数为1.29万户，较3月31日增加2041户，增幅18.73%。户均持股数量由上期的4.26万股减少至3.6万股，户均持股市值为143.58万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","09939","BK0239","BK1515","159938","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793885476996,"stockEarnings":[{"period":"1week","weight":0.1033},{"period":"1month","weight":0.105},{"period":"3month","weight":0.2223},{"period":"6month","weight":0.18},{"period":"1year","weight":0.012},{"period":"ytd","weight":0.1128}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":-0.0406},{"period":"3month","weight":-0.0549},{"period":"6month","weight":-0.1181},{"period":"1year","weight":-0.0692},{"period":"ytd","weight":-0.0712}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13448人(较上一季度增加3.96%)","perCapita":"34296股","listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","registeredCapital":"46516万元","survey":" 迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。","listedPrice":52.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药-U(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药-U(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药-U,688192,迪哲医药-U股票,迪哲医药-U股票老虎,迪哲医药-U股票老虎国际,迪哲医药-U行情,迪哲医药-U股票行情,迪哲医药-U股价,迪哲医药-U股市,迪哲医药-U股票价格,迪哲医药-U股票交易,迪哲医药-U股票购买,迪哲医药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药-U(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药-U(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}